As a global organization that includes a facility in Houston, the Charles River family was personally affected by the impact of Hurricane Harvey. The rest of Charles River remains in contact with those in Houston to continually assess the best way we can render aid.
Our bioanalytical team in Ashland, OH, has successfully validated an LC-MS/MS method for the assessment of thyroid hormones (T3 and T4) in late fetal and early neonatal rat serum.
Chemists and biologists working together, sharing knowledge and data across disciplines, is essential to successful drug discovery.
Brains On-Line’s unique portfolio of in vivo pharmacology and pharmacokinetics, combined with Charles River’s neurological drug discovery services will greatly increase the understanding of CNS disease pathophysiology, which is critical for new therapy development.
Bioassays help ensure the quality, safety, and efficacy of biological products. To meet the thriving biologics and biosimilar industry, lab capacities for bioactivity testing at our Erkrath, Germany site will be expanded by the end of Q3 2017.
Drastically reducing sample processing time, new SPARCL technology increases our capacity for large molecule bioanalysis.
Our new FT-IR spectrometer allows us to provide a more comprehensive package for protein higher order structural characterization.
Following redevelopment, our Lyon facility now boasts flexible housing for different species within a single building.
We’ve partnered with the global leader in aquaculture diagnostics and monitoring to extend our portfolio of zebrafish testing services in North America.
Combined ligand- and structure-based virtual screens are a successful hit finding approach in the discovery of LRRK2 inhibitors.